A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Public ClinicalTrials.gov record NCT06682988. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment
Study identification
- NCT ID
- NCT06682988
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Interventions
- Mirvetuximab Soravtansine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2025
- Primary completion
- Jun 30, 2026
- Completion
- Mar 31, 2028
- Last update posted
- May 25, 2026
2025 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| First Physicians Group /ID# 272180 | Sarasota | Florida | 34239 | Recruiting |
| St. Elizabeth Medical Center - Edgewood /ID# 272113 | Edgewood | Kentucky | 41017 | Recruiting |
| Baptist Health Lexington /ID# 272211 | Lexington | Kentucky | 40503 | Recruiting |
| UMass Memorial Medical Center - Belmont Street /ID# 272122 | Worcester | Massachusetts | 01605 | Recruiting |
| Karmanos Cancer Institute - Detroit /ID# 272112 | Detroit | Michigan | 48201 | Recruiting |
| Allegheny Health Network West Penn Hospital /ID# 272267 | Pittsburgh | Pennsylvania | 15244 | Recruiting |
| Memorial Hermann Texas Medical Center /ID# 272227 | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06682988, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 25, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06682988 live on ClinicalTrials.gov.